» Articles » PMID: 35179632

Cytokines and Chemokines Multiplex Analysis in Patients with Low Disease Activity Rheumatoid Arthritis

Overview
Journal Rheumatol Int
Specialty Rheumatology
Date 2022 Feb 18
PMID 35179632
Authors
Affiliations
Soon will be listed here.
Abstract

Rheumatoid arthritis is a severe chronic autoimmune disorder that results from pathological activation of immune cells and altered cytokine/chemokine network. The aim of our study was to evaluate concentrations of chosen cytokines and chemokines in blood sera and synovial fluid samples isolated from low disease activity rheumatoid arthritis (RA) patients and osteoarthritis (OA) sufferers. Blood sera and synovial fluid samples have been obtained from 24 OA and 14 RA patients. Cytokines/chemokines levels have been determined using a Milliplex Map 38-plex human cytokine/chemokine magnetic bead-based panel (Merck Millipore, Germany) and Luminex MAGPIX platform (Luminex USA). Low disease activity RA patients showed altered concentration of numerous cytokine/chemokine when compared to OA controls-they were characterized by, inter alia, increased: eotaxin/CCL11 (p = 0.037), GRO/CXCL1 (p = 0.037), IL-2 (p = 0.013), IL-4 (p = 0.017), IL-7 (p = 0.003), IL-8 (p = 0.0007) and GM-CSF (p = 0.037) serum levels, whilst MDC/CCL22 concentration was decreased in this group (p = 0.034). Eotaxin/CCL11 (p = 0.001), GRO/CXCL1 (p = 0.041), IL-10 (p = 0.003), GM-CSF (p = 0.01), IL-1RA (p = 0.0005) and VEGF (p = 0.01) concentrations in synovial fluid of RA females were also increased. Even with low disease activity score, RA patients exhibited increased concentrations of cytokines with pro- and anti-inflammatory activities, as well as numerous chemokines, growth factors and regulators of angiogenesis. Surprisingly, RA subjects also shown decreased concentration of CCL22 chemokine. The attempt to restore cytokine balance and tolerogenic environment is ineffective in RA sufferers even with good disease management. Distinguished factors could serve as possible indicators of disease progression even in low disease activity patients.

Citing Articles

Regulatory T lymphocytes as a treatment method for rheumatoid arthritis - Superiority of allogeneic to autologous cells.

Chmiel J, Stasiak M, Skrzypkowska M, Samson L, Luczkiewicz P, Trzonkowski P Heliyon. 2024; 10(17):e36512.

PMID: 39319132 PMC: 11419861. DOI: 10.1016/j.heliyon.2024.e36512.


The Effects of 21-Day General Rehabilitation after Hip or Knee Surgical Implantation on Plasma Levels of Selected Interleukins, VEGF, TNF-α, PDGF-BB, and Eotaxin-1.

Idzik M, Poloczek J, Skrzep-Poloczek B, Drozdz E, Chelmecka E, Czuba Z Biomolecules. 2022; 12(5).

PMID: 35625533 PMC: 9139046. DOI: 10.3390/biom12050605.


The Importance of CXCL1 in Physiology and Noncancerous Diseases of Bone, Bone Marrow, Muscle and the Nervous System.

Korbecki J, Gassowska-Dobrowolska M, Wojcik J, Szatkowska I, Barczak K, Chlubek M Int J Mol Sci. 2022; 23(8).

PMID: 35457023 PMC: 9024980. DOI: 10.3390/ijms23084205.

References
1.
Mohanty S, Kottam L, Gambardella A, Nicklin M, Coulton L, Hughes D . Alterations in the self-renewal and differentiation ability of bone marrow mesenchymal stem cells in a mouse model of rheumatoid arthritis. Arthritis Res Ther. 2010; 12(4):R149. PMC: 2945046. DOI: 10.1186/ar3098. View

2.
Raza K, Falciani F, Curnow S, Ross E, Lee C, Akbar A . Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther. 2005; 7(4):R784-95. PMC: 1175027. DOI: 10.1186/ar1733. View

3.
Bahlas S, Damiati L, Dandachi N, Sait H, Alsefri M, Pushparaj P . Rapid immunoprofiling of cytokines, chemokines and growth factors in patients with active rheumatoid arthritis using Luminex Multiple Analyte Profiling technology for precision medicine. Clin Exp Rheumatol. 2018; 37(1):112-119. View

4.
Rump L, Mattey D, Kehoe O, Middleton J . An initial investigation into endothelial CC chemokine expression in the human rheumatoid synovium. Cytokine. 2017; 97:133-140. PMC: 5516773. DOI: 10.1016/j.cyto.2017.05.023. View

5.
Saxena A, Khosraviani S, Noel S, Mohan D, Donner T, Hamad A . Interleukin-10 paradox: A potent immunoregulatory cytokine that has been difficult to harness for immunotherapy. Cytokine. 2014; 74(1):27-34. PMC: 4454631. DOI: 10.1016/j.cyto.2014.10.031. View